<DOC>
	<DOCNO>NCT01541865</DOCNO>
	<brief_summary>The Study objective ass performance Vessix V2 Renal Denervation System treatment uncontrolled hypertension use innovative percutaneous Radio Frequency ( RF ) balloon catheter renal denervation device .</brief_summary>
	<brief_title>Treatment Resistant Hypertension Using Radiofrequency Percutaneous Transluminal Angioplasty Catheter</brief_title>
	<detailed_description>This study evaluate hypothesis Vessix V2 Renal Denervation System employ reduce systolic diastolic blood pressure 6 month compare pre-treatment baseline blood pressure . Patient blood pressure measure office accord recognize international technique standard . Procedural success shall define ability complete renal denervation treatment use V2 balloon catheter device RF generator .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . Subjects provide write informed consent ; 2 . Subjects ≥ 18 year ≤ 75 year age ; 3 . Subjects Systolic Blood Pressure ( SBP ) ≥ 160 mm Hg base average three ( 3 ) officebased blood pressure reading ( seat ) measure accord protocol ; 4 . Subjects ≥ 3 antihypertensive drug maximally tolerate dos stable regimen least 2 week prior enrollment 5 . Subjects estimate glomerular filtration rate ( eGFR ) ≥ 45 ml/min/1.73m^2 ; 6 . Suitable renal artery anatomy 7 . Subjects willing able comply study procedure . 1 . Subjects known/diagnosed secondary hypertension ; 2 . Subjects contraindicate anticoagulation medication ( heparin , aspirin , Angiomax , etc . ) , analgesic medication ( morphine , fentanyl , etc . ) , anxiolytic medication ( alprazolam , lorazepam , diazepam , etc . ) medication require interventional procedure ; 3 . Subjects know bleed hypercoagulation disorder ; 4 . Subjects type 1 diabetes mellitus ; 5 . Subjects experience myocardial infarction , unstable angina pectoris , uncompensated heart failure , cerebrovascular accident within six ( 6 ) month prior screen visit , widespread atherosclerosis , document intravascular thrombosis unstable plaque ; 6 . Subjects plan percutaneous vascular surgical intervention reason within next 6 month ; 7 . Subjects hemodynamically significant valvular heart disease reduction blood pressure would consider hazardous ; 8 . Subjects implantable cardioverter defibrillator , pacemaker , clinically significant abnormal electrocardiogram 9 . Subjects serious medical condition , opinion investigator , may adversely affect patient safety efficacy procedure study ( i.e. , patient clinically significant peripheral vascular disease , abdominal aortic aneurysm , bleed disorder thrombocytopenia , hemophilia , significant anemia ) ; 10 . Subjects pregnant , nurse plan become pregnant ; 11 . Subjects know , unresolved history drug use alcohol abuse/dependency ; 12 . Subjects currently enrol investigational study wherein patient participation complete ; 13 . Subjects , reason , may able understand comply instruction ; 14 . Subjects contraindicate intravascular contrast material ; 15 . Subjects currently take estrogen estrogenlike compound . 16 . Subjects prior renal denervation procedure 17 . Subjects prior intervention right leave renal artery ; 18 . Subjects ≥ 30 % renal artery stenosis 19 . Subjects severe femoral , renal , iliac aortic calcification may cause potential complication time procedure ; 20 . Subjects physician unable safely cannulate renal artery ; 21 . Subjects physician unable percutaneously access femoral artery ; 22 . Subjects one kidney .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hypertension , renal denervation , uncontrolled hypertension , medication resistant hypertension</keyword>
</DOC>